Respiratory · BronchodilatorRegulatory Approvalcommercialnear-term

FDA Approves Albuterol Sulfate ANDA219409 from Cipla

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Cipla2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/20/2026, 6:31:35 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Cipla's ANDA219409 for Albuterol Sulfate introduces a new competitor in the respiratory market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the implications of this entry on their existing products and strategies. Regulatory context from FDA (FDA AP — ALBUTEROL SULFATE (ORIG)) supports the near-term read. Assessment grounded in 23 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Cipla's entry on market share and pricing strategies for existing products. The strongest clinical anchor is HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial (ClinicalTrials.gov), mechanism alignment (io ). In Respiratory · Bronchodilator, 6 regulatory and 7 competitive items passed relevance filtering for Cipla.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves CAPVAXIVE for At-Risk Children and Adolescents. This approval allows Cipla to enter the market for Albuterol Sulfate, increasing competition among existing players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ALBUTEROL SULFATE (ORIG) (FDA). Entity match (cipla); Regulatory pathway relevance (nda). The approval itself does not indicate any changes to regulatory compliance for existing products, but it does highlight the ongoing regulatory landscape for generic drugs.

Key Opportunities

Cipla's entry may lead to increased competition, potentially affecting pricing and market share for current players in the respiratory segment, which could impact revenue forecasts.
Portfolio teams should assess the impact of Cipla's entry on market share and pricing strategies for existing products.

What Would Change This Assessment

This becomes more urgent if Monitor market launch timelines and pricing strategies from Cipla and competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ALBUTEROL SULFATE (ORIG)
FDAhigh relevance
Entity match (cipla); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALBUTEROL SULFATE (ORIG)
FDAhigh relevance
Entity match (cipla); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALBUTEROL SULFATE (ORIG)
FDAhigh relevance
Entity match (cipla); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Breathlessness Perceptions Within Respiratory Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Mechanism of 'Yanjiu Needle' for Pharyngeal Dysphagia Based on sEMG Features
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves CAPVAXIVE for At-Risk Children and Adolescents
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves First Generic of Xofluza for Influenza Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves First Oral Carbapenem for Complicated UTIs
Humanexa Signalsmedium relevance
Moderate corpus alignment

Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Cipla
Albuterol Sulfate

Commercial impact

medium

Cipla's entry may lead to increased competition, potentially affecting pricing and market share for current players in the respiratory segment, which could impact revenue forecasts.

Regulatory impact

low

The approval itself does not indicate any changes to regulatory compliance for existing products, but it does highlight the ongoing regulatory landscape for generic drugs.

What to watch

Monitor market launch timelines and pricing strategies from Cipla and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.